glp 1 egfr cut off GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity CKJ REVIEW GLP-1 receptor agonists
Description
North America is dominating the GLP-1 analogues market, supported by a high prevalence of type 2 diabetes and obesity, strong healthcare infrastructure, and rapid adoption of innovative therapies
The drug has already been widely adopted in global markets due to its efficacy in glycemic control and additional metabolic benefits
Eli Lilly has also started manufacturing and stockpiling its GLP-1 pills so they're ready to hit the market once approval comes, NBCs Stephanie Gosk previously reported
Diabetes Obes Metab 22(4):492500
